The LA score identified three groups significantly different regarding the risk of HCC development after achieving SVR: a high-risk 2-point group (with levels of LOXL2 ≥ 2.08 ng/mL and of AFP ≥ 5.0 ng/mL), a medium-risk 1-point group (levels of either LOXL2 ≥ 2.08 ng/mL or of AFP ≥ 5.0 ng/mL), and a low-risk 0-point group (lower LOXL2 and AFP levels). This evidence concerns the gene LOXL2 and hepatocellular carcinoma.